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Abstract
We investigated the utility of 1,6-hexamethylene diamine (HDA) hemoglobin adducts as
biomarkers of exposure to 1,6-hexamethylene diisocyanate (HDI) monomer. Blood samples from
15 spray painters applying HDI-containing paint were analyzed for hemoglobin HDA (HDA-Hb)
and N-acetyl-1,6-hexamethylene diamine (monoacetyl-HDA-Hb) by GC-MS. HDA-Hb was
detected in the majority of workers (≤1.2–37 ng/g Hb), whereas monoacetyl-HDA-Hb was
detected in one worker (0.06 ng/g Hb). The stronger, positive association between HDA-Hb and
cumulative HDI exposure (r2 = 0.3, p < 0.06) than same day exposure (p ≥ 0.13) indicates long-
term elimination kinetics for HDA-Hb adducts. This association demonstrates the suitability of
HDA-Hb adducts for further validation as a biomarker of HDI exposure.
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Introduction
1, 6-Hexamethylene diamine (HDA) in biological media (e.g., urine, plasma) has been
utilized as a biological marker for occupational exposure to 1,6-hexamethylene diisocyanate
(HDI) (Maître et al. 1996, Williams et al. 1999, Rosenberg et al. 2002, Pronk et al. 2006,
Flack et al. 2010a). During automotive spray painting, workers may be exposed to HDI
present in paint formulations via skin or inhalation routes. In biological samples, these
markers represent the integration of HDI exposure across multiple exposure routes.
Repeated or prolonged exposure to HDI monomer and/or HDI oligomers (e.g., uretdione,
biuret, and isocyanurate) may also result in skin or respiratory sensitization (Zissu et al.
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1998, Pronk et al. 2007, Aalto-Korte et al. 2010) and development of occupational asthma
(Cockcroft & Mink, 1979, Vandenplas et al. 1993). Trace amounts of HDI monomer and
larger amounts of HDI oligomer as vapors and/or aerosols are produced during painting with
isocyanate-containing paints (Janko et al. 1992, Lesage et al. 1992, Sparer et al. 2004, Pronk
et al. 2006). Repeated skin exposure at these trace levels to HDI monomer (0.1%) may cause
skin sensitization, which can develop to asthma following inhalation exposure to HDI
monomer (Herrick et al. 2002). Therefore, characterizing and quantifying biomarkers of
HDI monomer exposure continues to be critical in evaluating workplace exposure,
developing strategies for mitigating exposure, and preventing adverse health effects.
HDA in acid-hydrolyzed urine and plasma are the only validated biomarkers to date for
short-term (Tinnerberg et al. 1995, Maître et al. 1996, Gaines et al. 2010) and cumulative
exposure to HDI monomer (Flack et al. 2010a). Once in the body, the isocyanato moiety
(NCO) may be hydrolyzed to an amine (e.g., HDA), catalyzed by bicarbonate in the blood
(Berode et al. 1991), or may react with proteins, such as albumin and hemoglobin (Hb), to
form protein adducts. HDA could be N-acetylated by N-acetyltransferase (NAT) to form N-
acetyl-1,6-hexamethylene diamine (monoacetyl-HDA) (Brorson et al. 1990a) and N,N′-
diacetyl-1,6-hexamethylene diamine (diacetyl-HDA), which is rapidly excreted. The amine
group may also undergo N-oxidation by cytochrome P450 or a flavin adenine dinucleotide–
dependent enzyme system, such as flavin-containing monooxygenase (FMO), and be further
oxidized to form reactive intermediates, such as nitroso derivatives (Gorrod, 1973,
Beedham, 1997). The oxidation pathway would eventually result in the formation of
isocyanate-derived protein adducts, with the potential to persist over the half-life of albumin
(t1/2 = 19 days) (Peters, 1975) or the lifespan of Hb (120 days) (Landaw, 1991). Individual
differences in acetylator genotype (fast vs. slow) that drive these dominant enzymatic-
directed pathways have been linked with asthma risk (Wikman et al. 2002). The non-
enzymatic formation of protein adducts may occur via hydrolysis of bis-dithiocarbamate
intermediates resulting from the reaction of NCO with thiols, such as cysteine (Chipinda et
al. 2006). In a human case study, HDI protein adducts were detected in lung tissue following
exposure to HDI, demonstrating that blood proteins are suitable markers for exposure and
target-dose estimation (Redlich et al. 1997). Different protein adducts or metabolites formed
from these various non-enzymatic or enzymatic-directed pathways following HDI monomer
exposure have not been fully characterized in exposed individuals. Such information would
help to identify important metabolic intermediates that are indicators of individual
susceptibility for asthma and other health effects.
The main advantage in measuring blood biomarkers of HDI exposure is to obtain internal
dose measures of cumulative exposures due to the formation of long-lived protein adducts.
The stronger correlation between HDA in acid-hydrolyzed plasma and dermal or inhalation
exposure to HDI monomer occurring ~0.5–2 months before blood collection compared with
the same day exposure among 46 spray painters demonstrated the presence of longer-lived
albumin adducts (Flack et al. 2010a). Moreover, a biphasic elimination pattern has been
described for diisocyanate-derived amines, thought to result from the rapid urinary excretion
of short-term metabolites within a few hours (Brorson et al. 1990b, Tinnerberg et al. 1995),
followed by the excretion of long-lived protein adducts days later (Lind et al. 1997). The
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presence of HDA in the majority of first-day, pre-exposure urine samples among HDI-
exposed spray painters, also indicated the slow elimination of protein conjugates
accumulated during the work week (Gaines et al. 2010). In addition to being an indicator of
past exposure to diisocyanates, protein adducts may contribute to the pathogenesis of
diisocyanate-induced asthma by their action as protein carriers in presenting HDI to the
immune system (Wisnewski et al. 2000). Therefore, the correlation between HDI exposure
levels and HDA-protein adducts in blood would provide additional information on the
uptake and elimination kinetics of HDI metabolites and, thus, the biological availability of
these reaction products in contributing to disease development.
The presence of Hb adducts may indicate cumulative exposure across a more extensive
period of time (≤120 days) compared with albumin adducts (19-day half-life) or free HDA
(several hours). A benefit of Hb adduct analysis is the enhanced specificity compared with
HDA analysis using acid-hydrolysis. Measured HDA from acid-hydrolyzed plasma (i.e.,
plasma HDA) or urine (i.e., urine HDA) may be derived from both unbound and protein-
conjugated HDA (e.g., albumin-HDA) and monoacetyl-HDA, as well as unbound diacetyl-
HDA. Acid treatment of plasma or urine masks individual variability in the types and yield
of various metabolites which, in turn, could provide information about susceptibility factors
and mechanisms related to disease development. Hb isolation followed by mild base
treatment has resulted in the identification of 4, 4′-methylene dianiline (MDA) and
monoacetyl-MDA adducts (Sepai et al. 1995), and these methods could be applied to blood
samples for identifying HDA-Hb and monoacetyl-HDA-Hb adducts.
The mechanism by which reactive diisocyanates are transported across the epithelial layer of
the respiratory tract, into the blood, and through the erythrocyte membrane to react with Hb
is unknown, but may involve the formation of mono- and bis-thiocarbamate intermediates
(Chipinda et al. 2006). Such products formed by the reaction of diisocyanate with cysteine
would allow transport across cellular membranes. It has been postulated that the bis-
thiocarbamate product could be carried from the lung to a distal site, whereupon hydrolysis
would occur, releasing a free diisocyanate that could react with another nucleophile
(Chipinda et al. 2006). Because the rates of hydrolysis among the different diisocyanate
intermediates vary widely, the biological availability of reactive intermediates may also
vary. Thus, investigation of HDA-Hb adducts would provide important information on
potential metabolic pathways and reaction products related to diisocyanate-mediated
hypersensitivity diseases.
There are no publications reporting the proportion of Hb to albumin adducts resulting from
HDI exposure and how these protein adduct levels vary with urine HDA levels. Sepai et al
(1995) reported MDA-Hb adduct levels in all 20 exposed workers to 4,4′-methylene
diphenyl diisocyanate (MDI), and monoacetyl-MDA was detected as Hb adducts in one
worker. However, the albumin adduct levels in plasma were 450-fold higher than the Hb
adduct levels. Whether albumin adducts are also the dominant products formed from HDI
exposure has yet to be investigated. Additionally, different levels of Hb adducts and urinary
MDA corresponding to MDI or MDA exposure and varying MDA-Hb levels by exposure
route (i.e., dermal or inhalation) have been observed (Pauluhn & Lewalter, 2002). In our
previous study, plasma HDA levels were modified by coverall use and type of ventilated
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paint booth that the workers used during spray painting (Flack et al. 2010a). Therefore,
exposure route, stability of metabolic intermediates, and exposure to the diisocyanate versus
the diamine (e.g., HDI vs. HDA) may drive specific metabolic pathways of HDI and,
consequently, the types and yields of products formed.
The objectives of this study were to: (i) quantify Hb adducts of HDA and monoacetyl-HDA
resulting from HDI exposure, using mild base treatment, in 15 exposed spray painters, and
(ii) investigate these measures as biomarkers of short- or long-term HDI exposure by
correlating levels of HDA in acid-treated plasma or Hb adducts with same day or cumulative
HDI monomer air, dermal, or inhalation exposure levels.
Materials and methods
Chemicals
Solvents and chemicals were purchased from Thermo Fisher (Hampton, NH): HPLC grade
(99.9%) dichloromethane (#AC61005–0040), ethyl acetate (#AC61006– 0040), acetonitrile
(#AC61001–0040), sodium sulfate anhydrous (certified ACS, #S421–500), acetic anhydride
(>99%, #AC14949–0010), sodium hydroxide (certified ACS, #S318–500), and Hb
(#ICN10071425); and from Sigma-Aldrich (St. Louis, MO): HDA (≥99%, #33000), 1,7-
diaminoheptane (98%, #D17408), and heptafluorobutyric anhydride (derivatization grade,
#394912).
Preparation of HDA and acetylated HDA (standard) mixture
A standard mixture of HDA, monoacetyl-HDA, and diacetyl-HDA was prepared by making
a 2 mg/ml solution of HDA in ethyl acetate (50 ml total volume). Acetic anhydride was
added dropwise at 0.9:1 molar ratio (acetic anhydride to HDA) with constant stirring at
room temperature. The solution was allowed to react for 2 h and was subsequently filtered
under vacuum using a 0.22 µm, 25 mm nylon filter. A portion of the filtrate was dried under
nitrogen and a 1 mg/ml solution of the dried product prepared in ethyl acetate. In order to
quantify the amount of diacetyl-HDA in the standard mixture, a solution of diacetyl-HDA
(≥99%) was synthesized by preparing a 2 mg/ml solution of HDA in ethyl acetate (50 ml
total volume) and adding acetic anhydride dropwise at 4:1 molar ratio (acetic anhydride to
HDA) with constant stirring at room temperature. The solution was allowed to react for 2 h
and was subsequently filtered under vacuum using a 0.22 µm, 25 mm nylon filter. A portion
of the filtrate was dried under nitrogen and a 1 mg/ml solution of the dried product prepared
in ethyl acetate. Gas chromatography–mass spectrometry (GC-MS) analysis of the diacetyl-
HDA mixture showed the product to be ≥99% pure (Flack et al. 2010b).
Preparation of HpDA and acetylated HpDA (internal standard) mixture
An internal standard (IS) mixture of 1,7-diaminoheptane (HpDA), monoacetyl-HpDA, and
diacetyl-HpDA was prepared by making a 2 mg/ml solution of HpDA in ethyl acetate (50 ml
total volume). Acetic anhydride was added dropwise at 0.9:1 molar ratio (acetic anhydride to
HpDA) with constant stirring at room temperature. The solution was allowed to react for 2 h
and was subsequently filtered under vacuum using a 0.22 µm, 25 mm nylon filter. A portion
Flack et al. Page 4






















of the filtrate was dried under nitrogen and a 1 mg/ ml solution of the dried product prepared
in ethyl acetate, and stored at 4°C.
Preparation of HDA and diacetyl-HDA standard curves
To quantify HDA, monoacetyl-HDA, and diacetyl-HDA in the standard mixture, calibration
standards of HDA and diacetyl-HDA were prepared in ethyl acetate. First, HDA and IS
solutions (1 µg/ml) were prepared. A 5 µg/ ml solution of diacetyl-HDA was prepared in
ethyl acetate. A 1:1 serial dilution (1 ml total volume) of HDA and diacetyl-HDA solutions
(in duplicate) was performed in ethyl acetate to obtain a concentration range: HDA (0–1 µg/
ml) and diacetyl-HDA (0–5 µg/ml). Each diluted sample of HDA or diacetyl-HDA was
spiked with 100 µl of 1 µg/ml IS mixture (final concentration = 0.1 µg/ml). Diluted standard
mixture solutions (5 µg/ml) were prepared in ethyl acetate (1 ml total volume) and spiked
with 100 µl of 1 µg/ml IS mixture. Solutions were reacted with 10 µl heptafluorobutyric acid
(HFBA) for 1 h at 55°C and immediately analyzed by GC-MS.
GC-MS analysis
Samples were analyzed by GC-MS (Thermo Trace GC Ultra interfaced with a PolarisQ ion
trap mass spectrometer and AI/AS 3000 injector, and Xcalibur 1.4 SR1 software; Thermo
Electron Corporation, Austin, TX). Injections (1 µl) were made under splitless mode of 30 s
with injector temperature of 220°C. Separation of the samples was carried out with a GC
capillary column (DB5-MS, 30 m × 0.25 mm ID, 0.1 µm film thickness; Agilent
Technologies, Palo Alto, CA). The ion source and GC transfer line temperatures were
maintained at 150 and 260°C, respectively. Helium was used as the carrier gas with a
constant flow of 1 ml/min. The GC oven temperature program was 50°C (1.0 min) to 155°C
at 10°C/ min, 155–185°C at 2°C/min, and 185–300°C at 25°C/min (final temperature held
for 10 min). Ions were monitored in negative ion chemical ionization mode using methane
as the reagent gas (1.8 ml/min). Mass spectra were acquired in the mass-to-charge ratio
(m/z) range 200–600.
GC-MS analysis of the standard curves and standard mixture revealed that the major ions
corresponding to derivatized HDA, monoacetyl-HDA, and diacetyl-HDA were m/z 448 [M–
60]– eluting at 14.1 min, 510 [M–40]–eluting at 15.1 min, and 552 [M–40]– eluting at 16.2
min, respectively (Figures 1 and 2). The major ion for HpDA, monoacetyl-HpDA, and
diacetyl-HpDA in the IS mixture was m/z 462 [M–60]− eluting at 15.6 min, 524 [M–40]−
eluting at 16.6 min, and 566 [M–40]− eluting at 17.7 min, respectively. The mass spectra for
each corresponding standard peak reflected successive losses of hydrogen (H) and fluorine
(F) atoms from derivatized parent amines (HDA = 508, monoacetyl-HDA = 550, diacetyl-
HDA = 592 g/mol) and IS amines (HpDA = 522, monoacetyl-HpDA = 564, diacetyl-HpDA
= 606 g/mol). Ion selection used in quantification of each amine was based on the most
abundant ion fragment in mass spectra.
Quantification of HDA and acetylated HDA in mixture
Peaks corresponding to HDA and acetylated HDA, as well as HpDA and acetylated HpDA
were integrated. Quantification of HDA and diacetyl-HDA in the standard mixture was
performed using a linear calibration graph of peak-area response of HDA to peak-area
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response of HpDA in calibration standards (r2 = 0.999) and a graph of peak-area response of
diacetyl-HDA to peak-area response of diacetyl-HpDA in calibration standards (r2 = 0.998),
respectively. The concentration of monoacetyl-HDA was calculated by subtracting the
known concentration of HDA and diacetyl-HDA from the total concentration (5 µg/ml). The
standard mixture yielded 0.09 µg/ml HDA (1.8%), 2.11 µg/ml monoacetyl-HDA (55.7%),
and 2.80 µg/ml diacetyl-HDA (42.5%).
Blood biomarker and exposure measurements
Fifteen spray painters (4 from North Carolina and 11 from Washington State) were
randomly selected from our HDI study population (Flack et al. 2010a). Blood samples were
collected during each sampling visit when workers consented (N = 35). Six workers were
sampled twice and eight workers were sampled three times. Blood was collected in EDTA
and heparin tubes at the end of the workday and plasma separated within 48 h of collection.
After the plasma and red blood cells (RBCs) were isolated, samples were stored at −35°C
until analyzed. Analyses for plasma HDA in acid-hydrolyzed samples have been published
elsewhere (Flack et al. 2010a). Briefly, 1 ml of plasma (in duplicate), containing 100 µl
sulfuric acid and HpDA IS, was baked at 100°C for 16 h. HDA was extracted three times
into 2 ml toluene, pooled extracts derivatized with 20 µl HFBA at 55°C for 1 h, and dried
under nitrogen. Samples were reconstituted into 60 µl ethyl acetate and analyzed by GC-MS.
Breathing-zone and dermal exposure measurements among these occupationally exposed
spray painters have been published elsewhere (Fent et al. 2009a, 2009b). Briefly, a personal
air sample in the worker’s breathingzone was collected during each spray painting operation
of HDI-containing paint. HDI on the skin was collected using three consecutive tape-strips
(10 cm2) applied to six different sites on the worker’s body (e.g., right and left forearms,
hands, and neck) after each paint task. Air and skin samples were analyzed by LC-MS as
previously described by Fent and colleagues (2009a, 2009b). Work diaries and
questionnaires about workers’ physical characteristics (e.g., age, height, weight), PPE use
(e.g., coveralls, respirator, gloves), and work environment (e.g., paint booth type, duration of
paint tasks) were completed during each visit.
Work-up procedure for Hb adducts
The sample work-up procedure was adapted from a previously published method describing
the analysis of Hb adducts of MDA and monoacetylated MDA (Sepai et al. 1995). The
separated RBCs (4 ml) were removed from −35°C storage and kept at room temperature
until thawed (~30 min). The Hb was precipitated from the lysate with 20 ml ethanol and
centrifuged (4000g, 10 min). The precipitate was washed with a series of organic solvents
(20 ml each of 1:1 ethanol:water, ethanol, 4:1 diethyl ether:ethanol, and diethyl ether), with
centrifuging between each wash. The Hb was dried in a dessicator at 4°C overnight.
Portions (200 mg) of Hb were dissolved in 4 ml sodium hydroxide (0.1 M) in the presence
of IS mixture (final concentration 5 ng/g Hb). After 60 min at room temperature, the amines
were extracted (2x) from basic solution into 4 ml dichloromethane, vortexed for 2 min, and
then centrifuged for 10 min at 1000g. To achieve optimal separation, samples were frozen at
−35°C and then allowed to thaw at room temperature. The pooled extracts were dried over
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sodium sulfate and derivatized with 10 µl HFBA. After 60 min at room temperature, the
samples were dried under nitrogen using a TurboVap® LV Evaporator (Zymark Center;
Hopkinton, MA). The dried residues were dissolved in 200 µl ethyl acetate and placed in an
ultrasonic bath for several minutes. The sample solutions were transferred to GC vial inserts
and evaporated to dryness using a SpeedVac® (Savant Instruments Inc., Holbrook, NY).
The dried residues were dissolved in 60 µl ethyl acetate. One reagent blank and two
calibration standards were prepared with every set of Hb samples collected from the
workers. The samples were analyzed by GC-MS as described above.
Standard curve preparation for Hb adduct analysis
A 50 mg/ml solution of Hb was prepared in 0.1 M sodium hydroxide (100 ml total volume).
Portions (4 ml, in duplicate) of Hb solution were spiked with HDA and acetylated HDA
mixture to make concentration range (N = 7, in duplicate): HDA (0–0.045 ng/mg Hb),
monoacetyl-HDA (0–1.05 ng/mg Hb), and diacetyl-HDA (0–1.40 ng/mg Hb). Each sample
was spiked with IS mixture (final concentration 5 pg/mg Hb). Each calibration sample was
treated according to procedure for Hb adduct analysis. Samples were analyzed by GC-MS
according to the above procedure. The limit of detection (LOD) for HDA, monoacetyl-
HDA, and diacetyl-HDA was 1.2, 0.03, and 0.05 ng/g Hb, respectively, as determined using
the average of six peak areas with a signal-to-noise ratio ≥3.
Variable construction
The breathing-zone concentration (BZC) of HDI monomer for each paint task (µg/m3) was
multiplied by the total paint time (min) for each task and summed together to obtain a daily
air exposure level (µg/m3 × min). To obtain a daily inhalation exposure level (µg/m3 × min),
the BZC was divided by the assigned protection factor (APF) based on respirator type
(OSHA, 2006): none, APF = 1; air purifying (half face), APF = 10; air purifying (full
facepiece), APF = 50; supplied air (full facepiece or hood), APF = 1000; PAPR (full
facepiece or hood), APF = 1000. The dermal concentration from tape-strips (ng/mm3) were
summed together for each task, and the task-based dermal values were summed together to
obtain a daily dermal exposure level (ng/mm3). The concentrations of Hb adducts (ng/g Hb)
and plasma HDA (ng/ml) were used in the data analysis.
Statistical analysis
The percent coefficient of variation (CV) was calculated for Hb adduct analysis among
replicate samples. The correlation between Hb adducts and plasma HDA and between Hb
adducts and HDI air or dermal exposure was investigated using linear regression analysis
(PROC REG procedure in SAS, version 9.1; SAS Institute, Cary, NC), with a significance
level of 0.10. For regression and summary statistics, all variables were natural log-
transformed to meet the assumption of normality (Shapiro–Wilk W > 0.80). Values of LOD/
√2 were assigned to all biomarker or exposure samples below the LOD.
Because plasma albumin has a circulating serum half-life of 19 days and Hb has a lifespan
of 120 days, we selected a biologically relevant time frame of 0–4 months of prior HDI
exposure to investigate the associations between biomarker and cumulative HDI exposure.
The end of the 4-month time frame would correspond to excretion of approximately 98%
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HDA-albumin adducts and 100% HDA-Hb adducts resulting from a single exposure to HDI.
These cumulative exposure estimates were obtained by summing the daily HDI air or dermal
concentrations across all repeated sampling visits for each worker. We investigated the
associations between cumulative HDI exposure and blood HDA biomarkers among workers
sampled on two or three repeated visits.
Results
The range of HDA-Hb adduct levels among NC workers (n = 4) was 1.3–6.6 ng/g Hb and
among WA workers (n = 11) was <1.2–37 ng/g Hb. The majority of samples were above the
LOD (95%) for HDA-Hb concentration. Monoacetyl-HDA-Hb was detected in one worker
(0.06 ng/g Hb). The CV among replicate Hb samples was in the range of 1–20%, which is
similar to those reported for plasma HDA, whereas spiked standards were in the range of 1–
10%. The lower quantitative precision among Hb samples compared with spiked standards
may be attributed to the release of amines from biological matrices affecting the variation in
recovered amines from Hb conjugates.
The range of HDA in base-treated Hb (N = 35) was ≤1.2–37, and in acid-treated plasma (N =
35) was ≤0.02– 0.71 ng/ml (Table 1). The majority of plasma samples (90%) were ≥LOD
for HDA. Figure 3 summarizes the average and the standard deviation for HDA-Hb adduct
and plasma HDA levels for each worker, arranged by increasing HDA-Hb level. The plot
depicts large within-worker variability in the biomarker levels and a weak association
between these biomarkers. The within-worker variability (>90%) comprised a greater
portion of the total variability in both HDA-Hb adduct and plasma HDA level. All BZCs
were ≥LOD whereas 40% of dermal exposure concentrations by paint task were ≥LOD. The
HDI monomer dermal exposure range was 2.0–38,100 ng/mm3; the HDI inhalation exposure
range was 0.034–864 µg/m3 × min, and the HDI air exposure range was 0.25–2570 µg/m3 ×
min (N = 35; Table 1).
Table 2 summarizes the regression analysis of HDA-Hb adducts or HDA levels in acid-
treated plasma versus same day or cumulative HDI dermal, inhalation, or air exposure. The
positive association between HDA-Hb adduct concentration and HDI exposure was
strongest with cumulative dermal (N = 12, r2 = 0.32, p = 0.058), cumulative inhalation (N =
12, r2 = 0.35, p = 0.042), or cumulative air exposure (N = 12, r2 = 0.34, p = 0.048). The
association between plasma HDA concentration and HDI exposure was strongest with
cumulative inhalation (N = 12, r2 = 0.32, p = 0.023) or cumulative air exposure (N = 12, r2 =
0.37, p = 0.036). Similar trends were previously reported for plasma HDA in the entire study
population (n = 46) in which stronger associations were observed with past HDI exposure
levels (Flack et al. 2010a). These different time-dependent associations (i.e., same day or
cumulative) between HDI air or dermal exposure and plasma HDA or HDA-Hb
concentration may be attributed to the half-life of albumin (19 days) and Hb lifespan (120
days), respectively.
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We developed a method to measure HDA-Hb and monoacetyl-HDA-Hb adducts as
biomarkers of HDI exposure using mild, alkaline treatment. Because monoacetyl-HDA-Hb
was only detected in one worker, further statistical investigation of these compounds was
not feasible. Additionally, the formation of diacetyl-HDA-Hb adducts would not be
anticipated based on the proposed metabolism of HDI (Flack et al. 2010b). However, the
methods described may be adapted to measure urinary diacetyl-HDA in future studies.
Using linear regression, we were able to demonstrate the utility of HDA-Hb adduct as a
biomarker of cumulative HDI dermal or inhalation exposure. The detection of HDA-Hb
adducts in the majority of blood samples indicates that HDA-Hb adducts are sufficiently
sensitive and specific as biomarker of cumulative exposure to HDI.
Deacetylation of acetylated amines in the presence of excess anhydride has been claimed to
be a critical issue during sample derivatization (Bailey et al. 1990, Schütze et al. 1995).
Although the extent of deacetylation was not determined in this study, the addition of 24 µg
4-methylaniline to spiked calibration samples prior to derivatization, in order to prevent
deacetylation (Schütze et al. 1995, Sepai et al. 1995), did not alter the relative yields of
HDA, monoacetyl-HDA, and diacetyl-HDA. Implementing additional steps in the sample
work-up method to avoid excess reagent (e.g., drying samples, limiting amount of reagent
used) would prevent deacetylation of acetylated amines (Joppich-Kuhn et al. 1997).
Therefore, deacetylation of monoacetyl-HDA was not expected to be significant in this
study.
We observed ~10-fold higher total circulating amounts of HDA-Hb adducts (GM = 2.5 µg,
GSD = 2.1) relative to HDA in acid-treated plasma (GM = 0.21 µg, GSD = 2.9), after
adjusting for plasma volume or blood volume (Svirbely & Iyengar, 1997) and using an
average male Hb concentration (16 g/dl). This relative abundance of different blood HDA
biomarkers is contrary to that found for other diamine biomarkers (e.g., plasma MDA >
MDA-Hb adducts) (Sepai et al. 1995). This may be related to differences in exposure route,
the stability of metabolic intermediates, or the differences in the chemical nature of the
protein-HDA bonds between aromatic and aliphatic amines, which could influence the
yields of various protein adducts (albumin vs. Hb). The bis-dithiocarbamate intermediate of
HDI, which can be easily transported into RBCs, is more stable compared to toluene
diisocyanate or MDI (Chipinda et al. 2006). Therefore, the stability of this metabolic
intermediate would allow greater opportunity for cellular uptake and subsequent Hb adduct
formation following further transformation. Another interesting point to consider is the
involvement of different enzyme systems in the metabolism of primary aliphatic amines
(e.g., HDA, monoacetyl-HDA) versus primary aromatic amines (e.g., MDA), which may be
oxidized primarily by cytochrome P450 (Guengerich & Shimada, 1991). The possible
involvement of FMO enzyme system, which participates in oxidation of basic aliphatic
amines (Beedham, 1997), in HDA metabolism may explain these differences in the types
and yields of various plasma and Hb adducts. Further research is needed to investigate the
chemical nature of these HDA-Hb bonds to better understand how these adducts are formed
and their role in disease development.
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Whether oligomers of HDI may be transformed to HDA through metabolic processes or
sample treatment (i.e., base or acid treatment) requires further investigation. Liu et al (2004)
demonstrated a stronger association between urinary HDA and HDI monomer air levels
compared to oligomers suggesting that HDA may be more indicative of monomer than
oligomer exposure. Knowledge on oligomer metabolism and their association with external
exposures is lacking, thus making HDA the only valid biomarker for HDI monomer
exposure. At present, investigation of biomarkers related to HDI oligomer exposure is
hindered by the lack of analytical standards and available methods to quantify them. Given
that HDI products used in autobody shops contain larger quantities of HDI oligomers
compared to monomer, future research is needed to investigate alternative biomarkers that
would indicate exposure to these compounds.
The weak association between HDA in acid-treated plasma and HDA-Hb concentration
within the same blood sample may indicate varying elimination kinetics among blood
biomarkers. Because albumin has a half-life of 19 days, HDA-albumin adducts may be
broken down and eliminated by similar elimination kinetics. However, Hb has a lifespan of
120 days and excretion of HDA-Hb adducts could occur after a longer time frame. Thus, the
various long-term elimination kinetics of these metabolites (HDA-Hb adducts and plasma
HDA) may have important implications in HDI exposure monitoring and biological
availability of these adducts for disease development.
The varying time-dependent associations between HDA in acid-treated plasma or HDA-Hb
adducts and HDI dermal, inhalation, or air exposure indicated the utilization of plasma HDA
and HDA-Hb adducts as biomarkers of cumulative HDI exposure. The benefit of HDA-Hb
adduct analyses is obtaining measures of specific biomarkers that may be related to different
exposure routes and metabolic pathways contributing to disease development. Protein
adducts may be formed via enzymatic-directed pathways, such as conjugation of metabolites
to cysteine residues of glutathione by GST or oxidation of HDA or monoacetyl-HDA by
FMO. Polymorphisms in GST have been suggested to play an important role in the inception
of ill effects related to diisocyanate exposure (Piirilä et al. 2001). Therefore, individual
differences in how diisocyanates are metabolized and the types of products formed may be
important factors related to individual susceptibility for disease.
There were several limitations in our estimates of HDI exposure through the inhalation
route. All 15 workers wore a respirator during spray painting (83% wore half-face air
purifying, 8% wore full-face air purifying, and 8% wore supplied air) which would reduce
exposure through the inhalation route. However, inhalation exposure may occur due to
improper fit and maintenance of respirators, particularly among workers wearing air-
purifying respirators, and would contribute to the within- and between-worker variability in
biomarker levels. Because breathing-zone measures were taken outside of the respirator, we
were unable to adjust for these various factors in our HDI inhalation exposure estimations.
Therefore, by adjusting the APF in estimating inhalation exposure may underestimate the
workers’ true exposure if these issues were a concern. Despite these limitations in estimating
inhalation exposure, the associations between blood biomarker concentrations and inhalation
exposure estimates were slightly stronger than the associations with air exposure estimates
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indicating that adjusting for respirator use may better reflect exposure through the inhalation
route.
There were also several limitations in our estimates of HDI exposure through the dermal
route. The high percentage of non-detectable dermal exposure measures (60% of paint tasks)
for HDI monomer using tape-stripping of the skin limited our ability in making strong
conclusions about the dermal exposure route. However, several workers did not wear gloves
(13%) or coveralls (27%) and, thus, dermal exposure was a potential route for uptake of
HDI. Analytical methods to measure skin protein adducts from HDI exposure and secondary
exposure to HDA, the hydrolysis product of HDI, may result in better estimates of dermal
exposure. Additionally, there was a positive association between HDI dermal and inhalation
exposure (N = 35, r2 = 0.27, p = 0.0015). Therefore, the issue of high collinearity between
these exposure routes prevents drawing strong conclusions about the relative significance of
either route on internal dose. Nonetheless, we demonstrated a strong, positive association
between cumulative HDI dermal exposure and HDA-Hb adduct concentration, indicating the
potential contribution of dermal exposure to internal dose levels. Whether exposure route
(i.e., dermal vs. inhalation) or exposure type (HDI vs. HDA) has an impact on the type and
yield of protein adducts formed requires further investigation.
Another source of the within-worker variability in plasma HDA or HDA-Hb concentrations
may be the aging of PPE (e.g., coveralls, respirator filters) over long periods of use, which
would lead to eventual breakthrough of the material. Additionally, differences in exposure
route (e.g., dermal vs. inhalation) or exposure type (e.g., HDI vs. HDA) would also
contribute to both the within- and between-worker variability. Other sources of the between-
worker variability in biomarker concentrations may be related to genetic polymorphisms
affecting enzymes regulating HDI metabolism (e.g., GST, NAT). Future studies should
investigate whether differences in exposure route, PPE use, and genetic factors play a role in
predicting these biomarker levels. Such information could be used to understand the relative
importance of dermal and inhalation exposure, workplace covariates, and genetic factors on
susceptibility for developing adverse health effects.
Conclusions
We presented a method for quantifying HDA and monoacetyl-HDA in Hb from HDI-
exposed individuals and demonstrated the utility of HDA-Hb adducts as biomarkers of
exposure to HDI monomer. The time-dependent (same day versus cumulative) associations
between HDI dermal, inhalation, or air exposure and levels of HDA-Hb adducts or HDA in
acid-treated plasma demonstrate their potential utilization as biomarkers of cumulative HDI
exposure. Monoacetyl-HDA Hb adducts may have limited use as markers of HDI exposure
due to the low levels observed in this study population. We demonstrated that HDA-Hb
adducts are sensitive and specific biomarkers of HDI monomer exposure. Further
characterization of urine and blood biomarkers resulting from HDI exposure may reveal
important metabolic pathways contributing to individual susceptibility for disease.
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GC-MS chromatogram of various derivatized amines extracted from base-treated Hb
solution (50 mg/ml) spiked with standard mixture (per mg Hb: 0.010 µg HDA, 0.11 µg
monoacetyl-HDA, 0.14 µg diacetyl-HDA) and IS mixture (0.50 µg/mg Hb) with their
corresponding major fragment ion (m/z). (A) Monoacetyl-HDA spiked into Hb solution. (B)
Diacetyl-HDA spiked into Hb solution.
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GC mass spectra using negative ion chemical ionization mode (m/z 200–600) of (A)
derivatized monoacetyl-HDA (0.11 µg/ mg Hb) and (B) diacetyl-HDA (0.14 µg/mg Hb)
extracted from base-treated Hb solution (50 mg/ml) and spiked with standard mixture.
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Average values and standard deviations of HDA-Hb adduct (ng/g) and plasma HDA (ng/ml)
concentrations in each worker across sampling visits (n = 15) and arranged by increasing
HDA-Hb concentration.
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Table 1
Summary of the measured HDA-Hb adduct (ng/g Hb), HDA in acid-treated plasma (ng/ml), HDI dermal
(ng/mm3)a, HDI inhalation (µg/m3 × min)b, and HDI air (µg/m3 × min)c exposure levels among 15 automotive
spray painters.
Sample N GM GSD Range
HDA-Hb 35 3.0 2.0 1.3–37
Plasma HAD 35 0.061 2.7 0.012–0.71
HDI dermal exposurea 72 131 7.1 2.0–38,100
HDI inhalation exposureb 72 7.8 11 0.034–864
HDI air exposurec 72 72 6.1 0.25–2570
GM, geometric mean; GSD, geometric standard deviation; N, number of biological samples or task-based exposure values.
a
 (HDI dermal exposure)j, sum of HDI dermal concentration across all daily tasks (j) was obtained by calculating the sum of the dermal
concentration measured for each task and summing the task-based dermal values.
b
 (HDI inhalation exposure)j, sum of HDI inhalation concentration across all daily tasks (j) was obtained by dividing the measured breathing-
zone concentration by the OSHA assigned protection factor based on respirator type (OSHA, 2006) for each task, multiplying the adjusted
breathing-zone concentration for each paint task (µg/m3) by the paint time (min), and summing the task-based inhalation values.
c
 (HDI air exposure)j, sum of HDI air concentration across all daily tasks (j) was obtained by multiplying the measured breathing-zone
concentration for each paint task (µg/m3) by the paint time (min) for each task and summing the task-based air values.
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Table 2
Log-transformed concentration of HDA-Hb adduct (ng/g Hb) or HDAs in acid-treated plasma (ng/ml) on last
sampling visit versus the log-transformed same day or cumulative HDI dermal (ng/mm3), inhalation (µg/m3 ×
min), or air (µg/m3 × min) exposure level among workers sampled two (n = 4) or three times (n = 8).
Exposure route Time of HDI exposurea Blood HDA r2 p Valueb
Dermal Same day Hb 0.15 0.206
Plasma 0.033 0.571
Cumulative Hb 0.32 0.058
Plasma 0.13 0.255
Inhalation Same day Hb 0.22 0.126
Plasma 0.36 0.041
Cumulative Hb 0.35 0.042
Plasma 0.42 0.023
Air Same day Hb 0.18 0.173
Plasma 0.20 0.150
Cumulative Hb 0.34 0.048
Plasma 0.37 0.036
n, number of workers.
a
Same day or cumulative HDI exposure.
b
p Value determined using linear regression analysis; significant associations (p ≤ 0.10 based on the sample size) are bolded.
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